TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36078778
Drug: General physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physiotherapy for disease characteristics; control group treatment before discharge.
Study: 34021703
Drug: ML-based scoring
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-based scoring functions
Study: 35734895
Drug: Leucocyte‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte‐ and platelet‐rich fibrin (L‐PRF) application
Study: 35734895
Drug: L‐PRF application
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF application
Study: 34299891
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activity (Control)
Study: 32414547
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin administered to the levator labii superioris alaeque nasi muscle (Group 1)
Study: 32414547
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin administered to the orbicularis oris site (Group 2)
Study: 39197976
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA)
Study: 34760995
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy during 6-minute walk test (6MWT)
Study: 34760995
Drug: No fan
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fan therapy during 6-minute walk test (6MWT)
Study: 35984123
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride injection (0.08 mg/kg)
Study: 35987885
Drug: mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 25 mg once per day for 12 weeks
Study: 35987885
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg once per day for 12 weeks
Study: 33270306
Drug: Heparin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin without protamine reversal
Study: 36170895
Drug: Pharmacist-led pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pathway with 30% drug discount
Study: 36170895
Drug: Pharmacist-led pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pathway with 60% drug discount
Study: 36170895
Drug: Pharmacist-led pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pathway with 90% drug discount
Study: 34578798
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with monosodium glutamate (MSG) at 2.7 g/day during the second round of chemotherapy
Study: 35769355
Drug: Lobaplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin (30 mg/m²) added to docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Study: 35769355
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Study: 35769355
Drug: Lobaplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin (30 mg/m²) added to docetaxel and epirubicin.
Study: 35769355
Drug: Lobaplatin added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lobaplatin added to chemotherapy.
Study: 39669005
Drug: Intraarticular corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroid injections
Study: 33693494
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg SHR4640
Study: 33693494
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SHR4640
Study: 33693494
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg benzbromarone
Study: 616501576
Drug: Common three‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common three‐dose intramuscular priming series followed by a final booster at 6 months
Study: 616501576
Drug: Common three‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common three‐dose intramuscular priming series followed by a final booster at 12 months
Study: 616501576
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine regimens
Study: 34824000
Drug: O2 treatment
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O2 treatment over the protective face mask
Study: 35912143
Drug: Gamma globulin
Normalized name: Gamma globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma globulin combined with azithromycin sequential therapy
Study: 35912143
Drug: Azithromycin plus
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin plus comprehensive basic treatment
Study: 34138667
Drug: IGF‐1 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐1 injections combined with HSR training
Study: 34138667
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections combined with HSR training
Study: 33583341
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 40 mg
Study: 33933236
Drug: CT‐CONT (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐CONT (continuation of first-line fluorouracil/platinum-based chemotherapy)
Study: 33933236
Drug: CT‐DISC (discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐DISC (discontinuation of first-line chemotherapy)
Study: 33336218
Drug: Gantenerumab 1200
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab 1200 mg every 4 weeks
Study: 35094447
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% after TCA-CROSS
Study: 35094447
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection before TCA-CROSS
Study: 32513288
Drug: PK-guided dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided dosage adjustments of docetaxel-based chemotherapy
Study: 32513288
Drug: BSA-guided dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-guided dosage adjustments of docetaxel-based chemotherapy
Study: 35796651
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment plus GIP(3‐30)NH2
Study: 33772963
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of antihaemophilic factor (recombinant)
Study: 33772963
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion (BI) of antihaemophilic factor (recombinant)
Study: 35768101
Drug: Whole-body photobiomodulation
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body photobiomodulation therapy (NovoTHOR)
Study: 35088753
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg/d for 12 weeks)
Study: 36331522
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg empagliflozin
Study: 36331522
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg empagliflozin
Study: 33086400
Drug: Emicizumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 1.5 mg/kg once-weekly subcutaneous
Study: 35543853
Drug: IVB +
Normalized name: Intravenous bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB + vitamin D insufficient/deficient + oral vitamin D supplementation (Group 3)
Study: 33227785
Drug: Panic-Focused Psychodynamic
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic-Focused Psychodynamic Therapy (PFPP)
Study: 32985240
Drug: Maxillary protraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary protraction therapy in UCLP group
Study: 32985240
Drug: Maxillary protraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary protraction therapy in noncleft group
Study: 32985240
Drug: Maxillary protraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary protraction therapy in both groups
Study: 32375104
Drug: Fulacimstat 25
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 25 mg twice daily for 6 months
Study: 35531757
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mL of 2% solution)
Study: 34749782
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy (MST), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Study: 34749782
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral ultra-brief pulse width electroconvulsive therapy (RUL-UB-ECT), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Study: 34656515
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy at 4 points with a diode laser at 810 nm wavelength, 6 J (100 mW, 60 seconds/point)
Study: 35261590
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.375% bupivacaine
Study: 35261590
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of 0.375% bupivacaine
Study: 35261590
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.375% bupivacaine
Study: 34256171
Drug: Endodontic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic therapy with MPQ, intracanal medication, and 2 applications of aPDT (0.005% methylene blue, 660 nm, 90 seconds)
Study: 34256171
Drug: Endodontic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic Therapy with Mechanical Chemical Preparation (MPQ) and intracanal medication
Study: 34543779
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of antiseizure medication (ASM)
Study: 34543779
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of antiseizure medication (ASM)
Study: 33874660
Drug: Metronidazole placement
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole placement into gingival pockets; General therapy with Calcemin
Study: 33874660
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of metronidazole and Eplan; General therapy with alendronate and alphacalcidolum
Study: 33874660
Drug: Eplan and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplan and alendronate and alphacalcidolum based medicines
Study: 35141811
Drug: Clonazepam 0.5
Normalized name: clonazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 0.5 mg 30 min before bedtime for 4 weeks
Study: 35141811
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin 2 mg 30 min before bedtime for 4 weeks
Study: 34281467
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or ILI
Study: 34655087
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg intravenously, maintained at 5 mg/kg/h)
Study: 34655087
Drug: Low-dose remimazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remimazolam tosylate (0.25 mg/kg intravenously, maintained at 0.48 mg/kg/h)
Study: 34655087
Drug: High-dose remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose remimazolam tosylate (0.25 mg/kg intravenously, maintained at 0.6 mg/kg/h)
Study: 34655087
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate (both doses)
Study: 32331026
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SPN-812
Study: 32331026
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SPN-812
Study: 36105449
Drug: Mailuoning injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailuoning injection treatment
Study: 35414566
Drug: HUG-5 tool
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HUG-5 tool administered periodically in an outpatient clinic using a semi-automated workflow
Study: 32526771
Drug: Incremental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental oxygen uptake test on a treadmill before starting (neo-)adjuvant treatment and an exercise intervention
Study: 37728450
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of bupivacaine with 75 mcg of clonidine
Study: 37728450
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of bupivacaine
Study: 33893705
Drug: Control (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inhaled sevoflurane anaesthesia)
Study: 36317958
Drug: Cangrelor (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (bolus and infusion for 2 hours)
Study: 33864607
Drug: Testosterone treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone treatment, n = 6
Study: 33864607
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, n = 8
Study: 34068824
Drug: Average amount
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average amount of alcohol consumed weekly (in frequent drinkers with obesity)
Study: 34366153
Drug: Henagliflozin 10
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 10 mg in the fasted condition
Study: 34366153
Drug: Henagliflozin 10
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 10 mg in the fed condition
Study: 34366153
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal prior to henagliflozin administration
Study: 34212234
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (0.1% triamcinolone acetonide)
Study: 33846016
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of statin prescriptions
Study: 34114493
Drug: Cellular medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular medicine trials (including stem cell therapy) for COVID-19
Study: 34114493
Drug: COVID-19 cellular
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 cellular medicine trials
Study: 35775704
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (c-PDT)
Study: 35775704
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (dl-PDT)
Study: 32469304
Drug: L-carnitine and
Normalized name: Fat Burner with Chromium Picolinate, L-Carnitine and Iron Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine and piracetam (10 mL of a solution containing L-carnitine 100 mg/mL + piracetam 80 mg/mL)
Study: 32469304
Drug: L-carnitine and
Normalized name: Fat Burner with Chromium Picolinate, L-Carnitine and Iron Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine and piracetam
Study: 35386730
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy for PTSD (DBT-PTSD)
Study: 33109679
Drug: Oral hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydroxyurea 10-20 mg/kg daily for 6 months
Study: 35361632
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone intravenously for three consecutive days
Study: 34605100
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine administration
Study: 36424125
Drug: Prophylactic surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic surfactant nebulisation (SN) at 200 mg/kg (poractant alfa)
Study: 32974844
Drug: κ‐selenocarrageenan supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: κ‐selenocarrageenan supplementation at selenium (Se) levels of 2.0 μg/g
Study: 32740286
Drug: Sceletium tortuosum
Normalized name: Mesembryanthemum tortuosum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sceletium tortuosum (ST) extract (25-mg) supplementation
Study: 32306803
Drug: Low-dose multi-strain
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multi-strain probiotic (5 billion CFU)
Study: 32306803
Drug: High-dose multi-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multi-strain probiotic (25 billion CFU)
Study: 33629921
Drug: QX003S (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: QX003S (8 mg/kg)
Study: 32691938
Drug: Sequencing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequencing treatment of oral oxybutynin chloride after BTX‐A injections
Study: 32691938
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin chloride in monotherapy
Study: 33989683
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (observation)
Study: 32348007
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus Berberine (BA group)
Study: 35766242
Drug: Sensory integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integration therapy delivered over 26 weeks
Study: 35766242
Drug: Sensory integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integration therapy
Study: 33190575
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of cocoa-rich chocolate (99%) daily for 6 months
Study: 32840418
Drug: Rucaparib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (600 mg twice per day)
Study: 33899689
Drug: CALAS (Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS (Capsule of alkaloids from Alstonia scholaris leaves)
Study: 33369791
Drug: Procnew15s (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procnew15s (single inhalation of CO bolus with 15s breath hold)
Study: 33369791
Drug: Procnew30s (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procnew30s (single inhalation of CO bolus with 30s breath hold)
Study: 32868637
Drug: Resveratrol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 2.5 g + 0 mg piperine
Study: 32868637
Drug: Resveratrol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 2.5 g + 5 mg piperine
Study: 32868637
Drug: Resveratrol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 2.5 g + 25 mg piperine
Study: 36384321
Drug: Perineural hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural hypertonic saline injection (5%)
Study: 36384321
Drug: Foot acupoints
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot acupoints hypertonic saline injection (5%)
Study: 34553296
Drug: Lapatinib+capecitabine (L+C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib+capecitabine (L+C)
Study: 35331536
Drug: High flavonoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavonoid cocoa (10.79 mg/g)
Study: 35331536
Drug: Low flavonoid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavonoid cocoa (1.02 mg/g)
Study: 36012924
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (STAG)
Study: 33503289
Drug: ALPN-101 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALPN-101 (3 mg/kg SC)
Study: 33503289
Drug: ALPN-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALPN-101 (10 mg/kg IV)
Study: 33503289
Drug: ALPN-101 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALPN-101 (1 mg/kg IV, 4 weekly doses)
Study: 33503289
Drug: ALPN-101 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALPN-101 (various doses)
Study: 34980505
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP), administered in a maximum of three therapeutic fractions (TFs) over 3-5 days, with a neutralizing antibody titre of = 1:160 or = 1:80 if unavailable.
Study: 34980505
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP)
Study: 32811378
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual care physical therapy: 1 hour, 5 days/week)
Study: 34617309
Drug: Daily prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisolone (0.75 mg/kg/day)
Study: 34617309
Drug: Intermittent prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent prednisolone (0.75 mg/kg/day for first 10 days of every month)
Study: 32814747
Drug: HK‐LS HS‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HK‐LS HS‐1 supplement